Granulocyte–macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial)

X Thomas,P. Fenaux,Hervé Dombret,S. Delair,Francois Dreyfus,Hervé Tilly,Anne Vekhoff,Pascale Cony-Makhoul,V Leblond,Xavier Troussard,Catherine Cordonnier,T. De Revel,Marc A. Simon,Franck-Emmanuel Nicolini,Anne-Marie Stoppa,Maud Janvier,D. Bordessoule,Philippe Rousselot,M. Ffrench,Marie Jp,Eric Archimbaud

Granulocyte–macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial)

1999

Granulocyte–macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial)

Keywords:

Etoposide
Cancer research
Oncology
Antimetabolite
Mitoxantrone
Myeloid leukemia
Granulocyte macrophage colony-stimulating factor
Chemotherapy
Pharmacology
Medicine
Placebo-controlled study
Internal medicine
Cytarabine
Gastroenterology
Mucositis
Placebo
Surgery

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations